Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
$41.86
-1.4%
$36.97
$26.20
$63.50
$1.93B1.38548,976 shs1.10 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.19
-0.6%
$11.27
$8.02
$18.55
$7.05B1.675.18 million shs3.15 million shs
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$37.91
+3.6%
$31.69
$27.34
$60.87
$6.97B0.131.33 million shs3.83 million shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$92.50
+2.7%
$69.56
$14.14
$93.86
$7.50B0.211.33 million shs1.38 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
+1.00%+16.27%+7.23%+10.72%-1.78%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.22%+5.88%+11.20%+38.16%-22.34%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-2.79%+20.52%+13.00%-3.84%-17.31%
Verona Pharma plc stock logo
VRNA
Verona Pharma
+3.77%+7.23%+33.35%+37.78%+573.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
2.1557 of 5 stars
3.51.00.00.01.44.20.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.0664 of 5 stars
1.22.00.00.31.31.70.0
Legend Biotech Co. stock logo
LEGN
Legend Biotech
3.0593 of 5 stars
4.51.00.00.03.01.70.6
Verona Pharma plc stock logo
VRNA
Verona Pharma
2.3658 of 5 stars
2.63.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
3.00
Buy$94.60125.99% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.176.88% Upside
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$76.20101.00% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.10
Buy$87.44-5.47% Downside

Current Analyst Ratings Breakdown

Latest APGE, ELAN, VRNA, and LEGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/2/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $71.00
5/14/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$100.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$7.50 per shareN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.59$2.93 per share4.84$12.63 per share1.12
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$728.30M9.57N/AN/A$6.88 per share5.51
Verona Pharma plc stock logo
VRNA
Verona Pharma
$118.54M63.27N/AN/A$3.10 per share29.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
-$83.99M-$3.60N/AN/AN/AN/A-21.81%-20.94%8/11/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7435.4815.942.504.60%6.78%3.03%8/6/2025 (Estimated)
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$0.59N/AN/AN/A-66.92%-29.69%-19.45%8/8/2025 (Estimated)
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$2.00N/A3,083.33N/AN/A-79.54%-43.49%8/14/2025 (Estimated)

Latest APGE, ELAN, VRNA, and LEGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/12/2025Q1 2025
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
-$1.19-$0.95+$0.24-$0.95N/AN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
4/29/2025Q1 2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.39
16.39
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.27
4.98
4.90
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.93
13.03
12.88

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.02%
Verona Pharma plc stock logo
VRNA
Verona Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics, Inc. stock logo
APGE
Apogee Therapeutics
9146.05 million28.77 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,070183.76 million182.60 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
3081.08 million76.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$41.86 -0.58 (-1.37%)
As of 04:00 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.19 -0.08 (-0.56%)
As of 03:59 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$37.91 +1.32 (+3.61%)
As of 04:00 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Verona Pharma stock logo

Verona Pharma NASDAQ:VRNA

$92.50 +2.45 (+2.72%)
As of 04:00 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.